Description
Provided by Parkinson & Movement Disorder Alliance
Hyperkinetic disorders can be difficult to diagnose, but correct identification is critical given the development of new treatments. This session focuses on Huntington’s chorea and tardive dyskinesia, two hyperkinetic disorders for which treatments are available. The session will cover the medications used to treat these disorders, including their mechanisms, efficacy, safety, and quality of life data based on clinical trials.
Estimated time to complete activity: 30 minutes
Accreditation Statement
In support of improving patient care, this activity has been planned
and implemented by PMD Alliance. PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Physician Continuing Medical Education
PMD Alliance designates this course for a maximum of .5 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.
Educational Objectives
After completing this activity, the participant should be better able to:
- Differentiate the clinical features and underlying mechanisms of Huntington’s chorea and tardive dyskinesia to improve diagnostic accuracy
- Evaluate the efficacy, safety, and mechanisms of action of pharmacologic therapies for Huntington’s chorea and tardive dyskinesia using recent clinical trial data
- Integrate evidence-based treatment strategies for Huntington’s disease and tardive dyskinesia into patient care plans to optimize functional outcomes and quality of life
Faculty
Fahd Amjad, MD
Assistant Professor of Neurology in the Movement Disorder Division and Co-Clinical Director of the Huntington Disease Care, Education and Research Center (CERC) at Medstar Georgetown University Hospital
Fahd Saeed Amjad, MD is a board-certified neurologist and Assistant Professor of Neurology in the Movement Disorder Division and Co-Clinical Director of the Huntington Disease Care, Education and Research Center (CERC) at Medstar Georgetown University Hospital in Washington, DC. After receiving his medical degree from Georgetown School of Medicine he completed his internship training in internal medicine at MedStar Union Memorial Hospital in Baltimore, Maryland. He completed his neurology residency at Georgetown University Medical Center, where he served as academic chief resident. He also completed a two-year fellowship in movement disorders at MedStar Georgetown University Hospital. His special interests include the medical and surgical management of Parkinson disease, essential tremor and dystonia. He is also experienced in the treatment of Parkinson’s Plus Syndromes, ataxia, tardive dyskinesia, Huntington Disease and tic disorders. He specializes in therapeutic botulinum toxin injections for blepharospasm, spasticity, dystonia and sialorrhea.
Disclosure of Relevant Financial Relationships
Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:
- Fahd Amjad, MD
- Site investigator for research supported by Roche and Merz
- Speakers’ Bureau, consultant, and/or advisory board member for Teva, Neurocrine, Acadia, AbbVie, Amneal, Supernus, and Kyowa Kirin
Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:
- Leslie Cloud, MD
- Site investigator for research supported by Amneal and Intracellular Therapies
- Speakers’ Bureau, consultant, and/or advisory board member for Amneal
- Britt Stone, MD
- Speakers’ Bureau, consultant, and/or advisory board member for Boston Scientific
- Jason Rivera, MPH
- No disclosures to report
- Clarisse Goas, NP
- Principal or site investigator for research supported by AskBio
- Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America
- Anissa Mitchel, LCSW
- No disclosures to report
- Kelly Papesh, DNP
- Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America
- Mary Ann Chapman, PhD
- Consultant for Allergan Aesthetics
- Fernando Pagan, MD
- Site investigator for research supported by Amneal and Kyowa Kirin
- Other grant support from Medtronic
- Speakers’ Bureau, consultant, and/or advisory board member for AbbVie, Acadia, Amneal, Acorda, Kyowa Kirin, Teva, Supernus, Merz, and Neurocrine
- Yasar Torres-Yaghi, MD
- No disclosures to report
PMD Alliance has received non-CME educational funding and support from ineligible companies. This support is not tied to continuing medical education. These relationships have been mitigated and do not influence CME content.
All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
This activity is supported by independent medical education grants from Merz, AbbVie, Kyowa Kirin, and Mitsubishi Tanabe Pharma America.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Request for Credit
In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.
If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org
